MIT ENTERPRISE FORUM OF NEW YORK CITY, INC.

presents

BEYOND GENOMICS

"The Protein Factor"

Co-sponsored by Technology Review

Now that the human genome is mapped, proteins replace genes as the next new thing in biotechnology. Just as genomics attempts to decipher all of the genes of an organism, protemics aims to uncover all of the proteins of an organism - and all of the functions and interactions of those proteins. Medical science is intent on discovering a new bounty of protein-based therapeutics and "small molecule" protein targets. Some 70 startups in this space have raised $700 million from venture capitalists and IPOs since June, 2000.

Will you hand your doctor a copy of your protemics identity on a "smart" card before treatment? Will in silico screens shorten clinical trials? When will protemics deliver narrowly targeted therapeutics - without side effects? When will "protemic" therapeutics reach the market and which will be first?

What's next in the march of the "-omics"?

Join us as we explore these questions and more.

Moderator:

• John Benditt,Editor in Chief, Technology Review

Panelists:

• Jonathan Rothberg, Chief Executive Officer, CuraGen
• David Zopf, Vice President, Neose Technologies
• Stephen Naylor, Chief Technology Officer, Beyond Genomics Inc.
• Winton Gibbons, Principal, Analyst & Group Head—Heathcare, William Blair & Company
• David Witzke, Analyst—Biotechnology Team, Credit Suisse First Boston